HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Financial Disclosures All Versions of this Article: clinchem.2006.084715v1 53/4/547    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, A. H.B. Search for Related Content PubMed PubMed Citation Articles by Wu, A. H.B. Related Collections Laboratory Management Evidence Based Laboratory Medicine and Test Utilization National Academy of Clinical Biochemistry Proteomics and Protein Markers

National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes

¹ Hennepin County Medical Center, Minneapolis, MN.
² Medical College of Virginia, Richmond, VA.
³ Duke University Medical Center, Durham, NC.
⁴ University of California at San Francisco, San Francisco, CA.
⁵ University of Maryland School of Medicine, Baltimore, MD.

NACB COMMITTEE MEMBERS, Robert H. Christenson, Chair

Baltimore, MD

Fred S. Apple

Minneapolis, MN

Christopher P. Cannon

Boston, MA

Gary Francis

Cleveland, OH

Robert Jesse

Richmond, VA

David A. Morrow

Boston, MA

L. Kristin Newby

Durham, NC

Jan Ravkilde

Aarhus, Denmark

Alan B. Storrow

Nashville, TN

Wilson Tang

Cleveland, OH

Alan H.B. Wu

San Francisco, CA

IFCC COMMITTEE ON STANDARDIZATION OF MARKERS OF CARDIAC DAMAGE (C-SMCD) MEMBERS, Fred S. Apple, Chair

Minneapolis, MN

Robert H. Christenson

Baltimore, MD

Allan S. Jaffe

Rochester, MN

Johannes Mair

Innsbruck, Austria

Jordi Ordonez-Llanos

Barcelona, Spain

Franca Pagani

Brecia, Italy

Mauro Panteghini

Milan, Italy

Jillian Tate

Brisbane, Australia

Alan H.B. Wu

San Francisco, CA

^aAddress correspondence to this author at: Director, Rapid Response Laboratories, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD 21201. Fax 410-328-5880; e-mail rchristenson@umm.edu.

The first 300 words of the full text of this article appear below.

	Introduction

 

• I. OVERVIEW OF ANALYTICAL ISSUES FOR ACUTE CORONARY SYNDROME (ACS) BIOMARKERS...548
  
• • A. Analytical Issues: Background...548
    
  
  
• II. ANALYTICAL BIOMARKER ISSUES...548
  
• • A. Cardiac Troponin Specifications...548
    
  • B. Cardiac Biomarker Turnaround...549
    
  • C. Biomarkers No Longer Recommended for Use in the Context of ACS...549
    
  • D. Determining Biomarker Decision Cutoff Characteristics for ACS...549
    
  • E. European Society of Cardiology (ESC)/American College of Cardiology (ACC) Recommendations...550
    
  
  
• III. REFERENCES...550
  

	I. Overview of Analytical Issues for Acute Coronary Syndrome (ACS) Biomarkers

 
a. Background
In 1999, the National Academy of Clinical Biochemistry (NACB)¹ published the first standards of laboratory practice addressing analytical and clinical recommendations for use of cardiac markers in coronary artery diseases (1). The objectives were to recommend the appropriate implementation and utilization of cardiac biomarkers, specifically for cardiac troponin (cTn), which had just gained US Food and Drug Administration (FDA) clearance as a cardiac biomarker to aid in the diagnosis of acute myocardial infarction (AMI). In 2001, the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD) recommended quality specifications for analytical and preanalytical factors for cTn assays (2). The objectives were intended for use by the manufacturers of commercial assays and by clinical laboratories that use cTn assays. The overall goal was to establish uniform criteria so that all cTn assays could objectively be evaluated for their analytical qualities and clinical performance. These general principles can also be applied to creatine kinase MB (CK-MB) mass and myoglobin assays by use of the analytical recommendations in this document. In this report, we provide the background for establishing updated practice guidelines with recommendations addressing analytical issues for cardiac biomarkers based on 8 years of evidence-based medical and scientific observations since the publication of the initial recommendations (1).

	II. Analytical Biomarker Issues

 
recommendations: analytical aspects of acs biomarkers
ALL CLASS I

1. Reference decision-limits should be established for each cardiac biomarker based on a population of normal, healthy individuals without a known history of heart disease (reference . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				D. A. Morrow and E. M. Antman Evaluation of High-Sensitivity Assays for Cardiac Troponin Clin. Chem., January 1, 2009; 55(1): 5 - 8. [Full Text] [PDF]

				F. S. Apple, S. W. Smith, L. A. Pearce, and M. M. Murakami Assessment of the Multiple-Biomarker Approach for Diagnosis of Myocardial Infarction in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome Clin. Chem., January 1, 2009; 55(1): 93 - 100. [Abstract] [Full Text] [PDF]

				A. Mingels, L. Jacobs, E. Michielsen, J. Swaanenburg, W. Wodzig, and M. van Dieijen-Visser Reference Population and Marathon Runner Sera Assessed by Highly Sensitive Cardiac Troponin T and Commercial Cardiac Troponin T and I Assays Clin. Chem., January 1, 2009; 55(1): 101 - 108. [Abstract] [Full Text] [PDF]

				F. S. Apple, M. M. Murakami, R. Ler, D. Walker, M. York, and for the HESI Technical Committee of Biomarkers Wor Analytical Characteristics of Commercial Cardiac Troponin I and T Immunoassays in Serum from Rats, Dogs, and Monkeys with Induced Acute Myocardial Injury Clin. Chem., December 1, 2008; 54(12): 1982 - 1989. [Abstract] [Full Text] [PDF]

				A. K. Saenger and A. S. Jaffe Requiem for a Heavyweight: The Demise of Creatine Kinase-MB Circulation, November 18, 2008; 118(21): 2200 - 2206. [Full Text] [PDF]

				J. R Tate, W. Ferguson, R. Bais, K. Kostner, T. Marwick, and A. Carter The determination of the 99th centile level for troponin assays in an Australian reference population Ann Clin Biochem, May 1, 2008; 45(3): 275 - 288. [Abstract] [Full Text] [PDF]

				K. Thygesen, J. S. Alpert, A. S. Jaffe, H. D. White, and On behalf of the Joint ESC/ACCF/AHA/WHF Task Force The universal definition of myocardial infarction: some issues and concerns: reply Eur. Heart J., May 1, 2008; 29(9): 1209 - 1210. [Full Text] [PDF]

				F. S. Apple, S. W. Smith, L. A. Pearce, R. Ler, and M. M. Murakami Use of the Centaur TnI-Ultra Assay for Detection of Myocardial Infarction and Adverse Events in Patients Presenting With Symptoms Suggestive of Acute Coronary Syndrome Clin. Chem., April 1, 2008; 54(4): 723 - 728. [Abstract] [Full Text] [PDF]

				P. Collinson, K. Pulkki, J. Suvisaari, J. Ravkilde, A. Stavljenic-Rukavina, A. Hammerer-Lercher, H. Baum, M. P. van Dieijen-Visser, and P. H. Laitinen How Well Do Laboratories Follow Guidelines on Cardiac Markers? The Cardiac Marker Guideline Uptake in Europe Study Clin. Chem., February 1, 2008; 54(2): 448 - 449. [Full Text] [PDF]

				S. E.F. Melanson, M. J. Tanasijevic, and P. Jarolim Cardiac Troponin Assays: A View From the Clinical Chemistry Laboratory Circulation, October 30, 2007; 116(18): e501 - e504. [Full Text] [PDF]

				F. S. Apple and M. M. Murakami Serum and Plasma Cardiac Troponin I 99th Percentile Reference Values for 3 2nd-Generation Assays Clin. Chem., August 1, 2007; 53(8): 1558 - 1560. [Full Text] [PDF]